FTC, seven states seek contempt ruling against Martin Shkreli
AI-generated briefing · First published
FTC and seven states accuse Shkreli of violating a 2022 lifetime ban from the pharmaceutical industry by trading at least 60 pharma stocks since his 2022 release.
The Federal Trade Commission and seven states asked a federal court on Tuesday to hold Martin Shkreli in contempt for repeatedly violating a 2022 civil judgment that bars him for life from the pharmaceutical industry. [1] [2]
The agencies allege that since his May 2022 release from prison, Shkreli traded at least 60 pharmaceutical stocks and publicly commented on several companies' operations and management. [1]
The filing asks the court to order Shkreli to divest all pharma holdings, pay a fine equal to all profits from the trades plus pre-judgment interest, and face escalating penalties for future violations. [1]
Sources
- 联邦贸易委员会及多州指控：马丁・什克雷利违反制药行业终身从业禁令
Sina Finance · · Full text
- ‘Pharma Bro’ Martin Shkreli is in trouble with regulators again, this time for influencing biopharma stocks
MarketWatch · · Summary only